Product Pathways - Jak/Stat Pathway
IL-1RA (20D8) Mouse mAb #3865
|3865S||100 µl (10 western blots)||---||In Stock||---|
|3865||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
IL-1RA (20D8) Mouse mAb detects endogenous IL-1RA protein. It does not cross-react with other related proteins.
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant human IL-1RA protein.
The founding members of the interleukin-1 (IL-1) superfamily include pro-inflammatory cytokines IL-1α and IL-1β, and a third protein that acts as an IL-1 receptor antagonist (IL-1RA). At least six similar proteins have been recently identified, including a homolog of IL-1RA (IL1F5). The three better-characterized proteins (IL-1a, IL-1b and IL-1RA) are mainly expressed in macrophages, monocytes, and dendritic cells. IL-1a and IL-1b act as potent inflammatory cytokines that help regulate host defense and immune responses (1). Binding of these pro-inflammatory cytokines to an IL-1 receptor recruits adapter proteins (such as IRAK) to the receptor. Phosphorylation of these adaptor proteins promotes downstream signaling cascades associated with the immune response (2). Altered expression of both IL-1a and IL-1b is associated with an extensive list of human disorders, including Alzheimer's disease, rheumatoid arthritis, psoriasis and various forms of cancer (3,4). IL-1RA acts as an anti-inflammatory cytokine, binding the IL-1 receptor to limit the response to inflammation (5). Because it plays a key role in regulating the inflammatory response, recombinant IL-1RA is a therapeutic agent used in the treatment of diseases such as rheumatoid arthritis. Alternatively, mutation of the corresponding IL-1RA gene may be associated with susceptibility to the development of specific cancers (6).
- Pelegrin, P. (2008) Drug News Perspect 21, 424-33.
- Ringwood, L. and Li, L. (2008) Cytokine 42, 1-7.
- Griffin, W.S. and Mrak, R.E. (2002) J Leukoc Biol 72, 233-8.
- Kamangar, F. et al. (2006) Cancer Epidemiol Biomarkers Prev 15, 1920-8.
- Arend, W.P. (2002) Cytokine Growth Factor Rev 13, 323-40.
- Sehouli, J. et al. (2002) Anticancer Res 22, 3421-4.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.